Provision of subsidized malaria drugs in shops improves uptake

Reporting the findings of a cluster randomized trial carried out in rural Kenya, Beth Kangwana and colleagues find that provision of packs of the malaria therapy artemether-lumefantrine in shops at a subsidized price more than doubled the proportion of children with fever who received drugs promptly.

Importantly, whilst enabling cheap and easy purchase of in shops enabled treatment of about 44% of children with fever, this is still much lower than the target of treating 80% of children with fever set by the Roll Back Malaria Partnership.

So in addition to this type of pragmatic solution to the problem of access to drugs, additional strategies will be required to boost the numbers of children with who are treated with antimalarials.

More information: Kangwana BP, Kedenge SV, Noor AM, Alegana VA, Nyandigisi AJ, et al. (2011) The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial. PLoS Med 8(5): e1000437. doi:10.1371/journal.pmed.1000437

Related Stories

Malaria makes relapsing fever more serious

date May 08, 2009

Malaria and the Borrelia infection relapsing fever are diseases with similar symptoms that can occur simultaneously. In such cases, the malaria is moderated while the relapsing fever becomes more serious. This is shown in ...

How to treat fevers in African children up for debate

date Jan 06, 2009

A new debate in the open access journal PLoS Medicine questions whether all African children with fever should be treated presumptively with antimalarial drugs, or if treatment should wait until laboratory tests confirm malari ...

Supplementary approach to malaria

date Feb 05, 2008

Could a simple vitamin A and zinc supplement help protect young children from malaria? A randomized double blind trial reported in the open access publication, Nutrition Journal, would suggest the answer is yes.

Recommended for you

US appeals court upholds delay in Alzheimer's drug swap

date 3 hours ago

A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.